Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End-stage Disease Clear all
Terminated Phase 2 Interventional Results available

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

NCT02664961
View directory record Official record
Conditions
Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor
Interventions
TRC105, Bevacizumab
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
16 Years to 99 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 22, 2026, 2:24 PM EDT
Recruiting No phase listed Observational

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

NCT05750498
View directory record Official record
Conditions
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Interventions
No interventions
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
8
States / cities
Palo Alto, California • Indianapolis, Indiana • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

NCT05614115
View directory record Official record
Conditions
End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic, Non-diabetic, Kidney Dysfunction, Kidney Failure, Hemodialysis
Interventions
Empagliflozin, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 22, 2026, 2:24 PM EDT
Withdrawn Phase 4 Interventional

Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease

NCT00573547
View directory record Official record
Conditions
Depression
Interventions
Fluoxetine
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 16, 2011 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Not applicable Interventional

Health Outcomes Patient Education

NCT02976220
View directory record Official record
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
Digital Education
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 22, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

STOP-T1D Low-Dose (ATG)

NCT04291703
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Antithymocyte Globulin, Placebo (for ATG)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 34 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Orange, California • San Francisco, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 22, 2026, 2:24 PM EDT
Withdrawn Phase 4 Interventional

Spironolactone Safety in Dialysis Patients

NCT00328809
View directory record Official record
Conditions
End Stage Renal Disease, Congestive Heart Failure
Interventions
spironolactone
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 22, 2026, 2:24 PM EDT
Completed No phase listed Observational

Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis

NCT00340119
View directory record Official record
Conditions
End Stage Renal Disease, ESRD
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 2:24 PM EDT
Terminated Not applicable Interventional Results available

Procurement of Leukapheresis Products From End Stage Liver Disease (ESLD) Patients for Immunological Studies

NCT02447926
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Leukapheresis
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Results available

Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection

NCT00163657
View directory record Official record
Conditions
End Stage Liver Disease, Hepatitis C
Interventions
Daclizumub, Tacrolimus, Cyclosporine, MMF
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 2:24 PM EDT
Completed No phase listed Observational

Biological Determinants of Peritoneal Dialysis

NCT02694068
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Peritoneal Equilibrium Test, 4 hour dwell of 2.5/4.25% dextrose solution
Other
Lead sponsor
University of Washington
Other
Eligibility
20 Years and older
Enrollment
4,865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 1 Interventional

End-stage Renal Disease (ESRD) Pilot Study

NCT03787368
View directory record Official record
Conditions
Renal Dialysis
Interventions
BAY1213790, 0.9% sodium chloride solution
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Chula Vista, California • Bradenton, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function

NCT01715259
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Abiraterone acetate: participants with end-stage renal disease, Abiraterone acetate: matched control participants with normal renal function
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 22, 2026, 2:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

NCT07763418
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Golcadomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 84 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 2:24 PM EDT
Completed No phase listed Observational

FREEDOM: Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements Study

NCT00288613
View directory record Official record
Conditions
Kidney Failure, Chronic, End Stage Renal Disease, Requiring Dialysis
Interventions
Not listed
Lead sponsor
NxStage Medical
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
41
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Garden Grove, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Not applicable Interventional

The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300

NCT05947708
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
Dialysate Flow Rate
Device
Lead sponsor
Outset Medical
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 22, 2026, 2:24 PM EDT
Recruiting Not applicable Interventional

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD

NCT07680283
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
IOUS-guided margin selection
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Not applicable Interventional

A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients

NCT00308295
View directory record Official record
Conditions
End-Stage Renal Disease Patients on Hemodialysis
Interventions
Fish oil capsules, matched placebo capsules
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 82 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2007 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Not applicable Interventional Results available

Monitoring in Dialysis -- a Prospective, Multi-center, Single-arm, Non-randomized, Observational Study in Patients Who Are Undergoing Hemodialysis.

NCT01779856
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
REVEAL Insertable Cardiac Monitor (ICM)
Device
Lead sponsor
Medtronic Corporate Technologies and New Ventures
Industry
Eligibility
21 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Augusta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Triferic Pediatric Pharmacokinetic Protocol

NCT02595437
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Loma Linda, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 22, 2026, 2:24 PM EDT
Terminated Phase 4 Interventional

Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation

NCT00656266
View directory record Official record
Conditions
End-stage Liver Disease, Renal Insufficiency, Renal Failure
Interventions
mycophenolate mofetil, placebo medication
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 16 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Not applicable Interventional

Pediatric Kidney Transplant Without Calcineurin Inhibitors

NCT00023231
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Daclizumab, Methylprednisolone/prednisone, Mycophenolate mofetil, Sirolimus, Bactrim, Ganciclovir, Lipitor
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 2 Interventional

Meaning-Centered Psychotherapy in Advanced Cancer

NCT00067288
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Neoplasms
Interventions
Meaning-Centered Group Psychotherapy, Standard Supportive Group Psychotherapy
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 22, 2026, 2:24 PM EDT
Terminated Not applicable Interventional Results available

Effects of Exercise by Neuromuscular Stimulation in Dialysis Patients

NCT03517553
View directory record Official record
Conditions
Dialysis
Interventions
EMS users in ESRD
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 22, 2026, 2:24 PM EDT